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Background: Hereditary non-polyposis colorectal cancer (HNPCC)/Lynch syndrome (LS) is a cancer syndrome
characterised by early-onset epithelial cancers, especially colorectal cancer (CRC) and endometrial cancer. The aim
of the current study was to use SNP-array technology to identify genomic aberrations which could contribute to
the increased risk of cancer in HNPCC/LS patients.
Methods: Individuals diagnosed with HNPCC/LS (100) and healthy controls (384) were genotyped using the
Illumina Human610-Quad SNP-arrays. Copy number variation (CNV) calling and association analyses were performed
using Nexus software, with significant results validated using QuantiSNP. TaqMan Copy-Number assays were used
for verification of CNVs showing significant association with HNPCC/LS identified by both software programs.
Results: We detected copy number (CN) gains associated with HNPCC/LS status on chromosome 7q11.21 (28%
cases and 0% controls, Nexus; p = 3.60E-20 and QuantiSNP; p < 1.00E-16) and 16p11.2 (46% in cases, while a CN loss
was observed in 23% of controls, Nexus; p = 4.93E-21 and QuantiSNP; p = 5.00E-06) via in silico analyses. TaqMan
Copy-Number assay was used for validation of CNVs showing significant association with HNPCC/LS. In addition,
CNV burden (total CNV length, average CNV length and number of observed CNV events) was significantly greater
in cases compared to controls.
Conclusion: A greater CNV burden was identified in HNPCC/LS cases compared to controls supporting the
notion of higher genomic instability in these patients. One intergenic locus on chromosome 7q11.21 is possibly
associated with HNPCC/LS and deserves further investigation. The results from this study highlight the
complexities of fluorescent based CNV analyses. The inefficiency of both CNV detection methods to
reproducibly detect observed CNVs demonstrates the need for sequence data to be considered alongside
intensity data to avoid false positive results.
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Genetic variation explains a significant proportion of
susceptibility to common disease [1-5]. Copy number
variations (CNVs) are quantitative structural genetic var-
iations affecting the number of copies of a particular
genomic region (deletions or duplications of DNA seg-
ments) ranging from a kilobase to several megabases in
size and covering 12% of the human genome [6,7]. Dif-
ferent populations share a large percentage of CNV re-
gions and the closer the relationship, the greater the
sharing [8], e.g. populations from different continents
share ~40% of CNVs, while populations within the same
continent share ~50%. The widespread distribution of
CNVs across the genome suggests they can account for
a proportion of population variation in common disease
status. Mechanisms by which CNVs may influence dis-
ease risk include; impacting gene expression due to
interruption of coding sequences, gene dosage or on
neighbouring gene regulation [9-14]. Evidence reported
in the literature clearly shows that CNVs play an import-
ant role in disease development and phenotype expres-
sion [14-18]. Chromosomal deletions have been found
more prevalent than duplications in case–control studies
[19,20] and interestingly, microRNAs (miRNAs) and
miRNA-binding sites are concentrated in CNV regions
[21]. It has been suggested that the development of a
disease phenotype may not depend upon a single CNV
but rather a combination of various CNVs and other
genetic variations (e.g. single nucleotide polymorphisms
(SNPs)) [14]. Indeed, an increased global CNV burden
has been observed in schizophrenia, autism and short
stature which has been used as model for polygenic
traits that are highly heritable [20,22-24]. Nevertheless,
studies of CNV burden have also yielded inconclusive
results [25].
SNP genotyping platforms have been used for genome-
wide association studies (GWASs) to identify novel cancer
susceptibility loci [26,27], resulting in the discovery of
many novel low-penetrance colorectal cancer (CRC) loci
[28-32]. The ability to perform genome-wide studies of
large CNVs has been facilitated by advances in array com-
parative genomic hybridisation (array CGH) and the
development of CNV calling algorithms based on
high throughput SNP genotype data [33,34]. Several new
candidate genes potentially predisposing to early onset
CRC have been identified utilising arrayCGH [35]. In
light of these findings we used a high density SNP geno-
typing array, combined with in silico CNV calling to
search for CNVs potentially involved in hereditary non-
polyposis colorectal cancer (HNPCC)/Lynch syndrome
(LS). HNPCC/LS is an autosomal dominantly inherited
cancer predisposition associated with mutations in DNA
mismatch repair (MMR) genes or genes affecting expres-
sion of MMR genes [36-41]. MMR proteins confer severalgenetic stabilisation functions; they correct DNA biosyn-
thesis errors, ensure the fidelity of genetic recombination
and participate in the earliest steps of cellular checkpoint
control and apoptotic responses [42]. MMR gene defects
increase the risk of malignant transformation of cells, ul-
timately resulting in the disruption of one or several genes
associated with epithelial integrity. Current classification
schemes differentiate between LS patients harbouring mu-
tations in MMR genes and HNPCC patients who adhere
to the Amsterdam Criteria [43] or Bethesda guidelines
[44] where a pathogenic mutation in MMR genes has not
been detected with existing screening strategies. HNPCC
is also referred to as familial colorectal cancer-type X [45].
The population frequency of LS has been estimated at ap-
proximately 1 in 3000 individuals [46,47]. By 70 years of
age, 45% of men and 33% of women diagnosed with
HNPCC/LS will develop CRC and 15% of women will de-
velop endometrial cancer [48,49]. Given that mutations in
DNA mismatch repair genes are generally not consid-
ered to display distinct genotype-phenotype correla-
tions and are only identified in ~50% of individuals
with a clinical diagnosis of HNPCC, it has become ap-
parent that other genetic factors are likely to influence
disease development.
The aims of the current study were to search for gen-
omic regions that might contribute to the development
of CRC in HNPCC/LS families by identifying CNVs
which differentiate HNPCC/LS cases from healthy con-
trols and to ascertain the extent of genomic CNV bur-
den between cases and controls and in the context of
potential MMR deficiency. We have identified one
locus in an intergenic region on chromosome 7q11.21
possibly associated with disease risk in patients diag-
nosed with HNPCC/LS and observed a greater CNV
burden in cases compared to controls. The results from




The sampling frame for this study was 833 LS/HNPCC
families tested at Hunter Area Pathology Service between
the years of 1997 and 2010. All patients included in the
study gave informed consent for their de-identified DNA
and clinical records to be used for future research related
to their condition. Ethics approval was obtained from the
Hunter New England Human Research Ethics Committee
and the University of Newcastle’s Human Research Ethics
Committee. Each participant had previously contributed
blood from which DNA was extracted using the salt pre-
cipitation method [50]. For the current study, from the set
of available families we selected 100 unrelated LS/HNPCC
cases (see Table 1) and 384 healthy controls from the
Hunter Community Study [51].
Table 1 Illustration of samples used in the study
Cases Diagnosed with extra colonic cancer Diagnosed with a second CRC
LS cases (mutation positive) 64* 23 (36%) 14 (22%)
HNPCC cases (mutation negative) 36** 10 (28%) 0
Total 100 33 (33%) 14 (14%)
* All but 3 adhered to the Amsterdam II criteria or the Bethesda guidelines.
** All but 1 adhered to the Amsterdam II criteria or the Bethesda guidelines.
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All samples were genotyped using the Illumina Human
610-Quad BeadChip (Illumina Inc., San Diego, CA, USA)
which contains 620,901 markers. In addition to evenly
spaced and comprehensive tag SNPs the Human610-Quad
BeadChip includes ~60,000 CNV-targeted markers in re-
gions containing known CNVs. Median spacing between
markers is 2.7 kb (mean 4.7 kb). The BeadChips were
processed by the same technician over a three months
period; the samples were not randomized as the control co-
hort used for this study was part of a larger longitudinal
study of health and aging in healthy adults [51]. BeadChip
data was processed using GenomeStudioV2010.1 (Illumina
Inc.) according to the manufacturer’s description. Primary
data analyses, including raw data normalisation, clustering
and genotype calling were performed using algorithms in
the genotyping (GT) Module. The software derives, for
each sample, log R ratios (LRR) and B allele frequencies
(BAF) for each probe on the 610-Quad array; the LRR re-
flects relative probe fluorescence intensity, which varies
with the discrete number of copies of probe-specific DNA
present within an individual’s genome.
The LRR and BAF values were used as input for Nexus
Copy Number Software, Version 5 (BioDiscovery, El
Segundo, CA, USA). A copy number state of 2 per indi-
vidual is considered normal (one copy per chromosome);
lower values reflect copy number loss and higher values
a copy number gain. Nexus, used for CNV calling and
association analyses, offers several algorithms for CNV
detection; the SNPRank segmentation algorithm was
used based on a previous report demonstrating its low
type I error rate and high power compared with a range
of available algorithms [34]. A significance threshold of
0.01 was required for declaring the presence of a seg-
ment; a threshold empirically identified as the value
which minimised the normalised singleton ratio (NSR)
parameter in a training set of ten randomly chosen sam-
ples from our sample cohort. NSR has previously been
demonstrated as a useful optimisation parameter for
CNV detection and is calculated as the proportion of
unique CNV SNPs found in only 1 sample divided by
the average number of CNV SNPs called per sample
[34]. The following analyses settings were applied in
Nexus to define a CNV: A minimum of 5 probes persegment (increased from default 3), high gain = 0.6 LRR
(default), gain = 0.18 LRR (default), loss = −0.18 LRR (de-
fault) and big loss = −1.0 LRR (default). For the associ-
ation testing the p-value threshold was also set to 0.01
and the differential threshold was set at default 25%.
To minimise the impact of type I error (resulting from
incorrectly called CNVs) upon our conclusions, all CNV
regions demonstrating significant association using
Nexus (see below for statistical methods) were inde-
pendently tested for validity using QuantiSNP software
Version 2.3 Beta (Wellcome Trust Centre for Human
Genetics) [52]. Both programs infer CNV states from
array data based on LRR and BAF; the difference be-
tween the two methods is the iterative mathematical
methods utilised: QuantiSNP uses an objective Bayes
hidden-Markov model, while Nexus SNPRank uses a
segmentation algorithm (a variation of the circular bin-
ary segmentation) that recursively divides chromosomes
into segments of common intensity distribution. The de-
fault program settings were used in QuantiSNP for de-
fining copy number states: EM-iters – the number of
iterations used in training the model on the experimen-
tal data; L-setting – expected typical number of base
pairs in a CNV-region (smoothing factor); and the
maxcopy setting – maximal CN state value in the Mar-
kov model. GC-correction is applied by default to
smooth out genomic waving. Association analyses was
performed only for CNVs called with high confidence
(maximum log Bayes Factor >10) containing a minimum
of 5 probes (changed from default 10).
As a final step to confirm the validity of events with
significant frequency differences, log R ratio plots were
visually inspected to ensure that called CN gains and
losses were visually evident and not simply artefacts of
the calling algorithm. Human genome build 18 (36.3)
has been used for assigning chromosome positions
throughout the manuscript.
Statistical analyses
Significance testing for group differences in individual
CNV frequencies was performed utilising Nexus Proto-
col 5 [53] for Nexus output, and t-test implemented in
Stata (version 10, StataCorp, College Station, TX) for
QuantiSNP results, where the predictor variable was the
quantitative copy number at each locus. To control the
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tests, a significance threshold of p < 3.6E-06 was used for
significance tests of individual CNV events; a threshold
derived by dividing the desired FWER of 0.05 by the
total number of non-overlapping CNVs tested for signifi-
cance. We note that this Bonferoni threshold is likely
conservative, owing to probable linkage disequilibrium
(correlation) between some adjacent, non-overlapping
CNVs. Statistical comparisons were performed only for
CNV events observed on autosomes, due to the com-
plexity of analysing the X and Y chromosomes.
For each individual, we also defined several measures
of autosomal genomic CNV burden and compared mean
values between phenotypic groups. CNV burden for
each individual was defined in three distinct ways; 1) the
total length of genomic DNA involved in identified CNV
events; 2) average length of CNVs; and 3) total number
of CNVs. Comparison of CNV burden between groups
was conducted using t-tests in Stata.
All results reported as statistically significant have
reached our pre-specified, adjusted significance thresh-
old using both Nexus and QuantiSNP results and also
shown a consistent direction of effect (frequency differ-
ence) using both algorithms.
Validation of significant CNVs
TaqManW Copy Number Assays (Applied Biosystems,
Carlsbad, CA, USA) were used to validate copy num-
ber state for CNVs showing significant case–control
frequency differences via in silico analyses. Because a
Custom TaqManW CN assay could not be designed for
the CN gain region of significance on chromosome
7q11.21 (61,682,801-61,827,108), a neighbouring down-
stream sequence between SNPs rs8188515 (61,789,558)
and rs4718336 (61,990,710) was submitted for Custom
assay design [NT_007933.15] – with forward and reverse
primers starting at position 61,860,925 and 61,861,034,
respectively (for primer and probe sequences, see
Table 2). Most of the samples harbouring the CN gain at
7q11.21 had a longer gain than the associated region,
which overlapped the assay design region. Therefore








FAM-dye labelled probe ACCTTTCCTTTGATTCAGCAGTTchromosome 16p11.2 CN gain (32,411,929-32,504,942)
the sequence between rs28778587 (32,419,415) and
rs4368167 (32,489,319) was used for assay design
[NT_010393.16] – with forward and reverse primers
starting at position 32,453,256 and 32,453,355, respect-
ively (for primer and probe sequences, see Table 2). Both
sequences were run on SNPmasker [54] before design
submission to eliminate allele specific amplification as a
result of SNPs in the primer regions (as required by the
manufacturing company).
The Custom TaqManW CN Assay is a quantitative PCR
assay (FAM-MGB dual-labelled probe) with RNaseP
(VIC-TAMRA dual-labelled probe) as the reference assay,
performed as a duplex reaction. The test assay, the refer-
ence assay, the DNA sample and TaqManW Master Mix
were combined according to manufacturer’s instruction
and run on an Applied Biosystems 7500 Real-Time
System. All samples were tested in triplicate using
20 ng of DNA per reaction. Analyses were performed
on a plate by plate basis, with analyses settings: Auto-
matic baseline, and manual CT threshold of 0.2 (as
recommended by the manufacturer). The CN for each
sample was assigned using CopyCaller™ software ver-
sion 2.0 (Applied Biosystems), which uses relative
quantitative analysis. The relative CN was determined
on the basis of the comparative ΔΔCT method with a
normal control DNA as the calibrator on each plate
(selected from the SNP array results to have 2CN). We
excluded wells with VIC CT greater than 32 and a zero
copy ΔCT threshold value of 4.0 (as recommended by the
manufacturer). A confidence level of 95% and z-score
value of <1.75 was applied to call the CNVs.
Results
Samples and genotyping
All samples retained for analyses showed a genome-wide
call rate >99.5% for the Illumina 610-Quad array. Four
samples were excluded from the analyses due to low call
rates (<99.5%) in GenomeStudio, high quality score
(>0.13) in Nexus and/or noisy log R ratio plots indicat-
ing poor genotyping efficiency. All four samples were LS
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Nexus software was used to conduct statistical compari-
sons of the frequency of each CNV event between cases
and controls, with a differential threshold of 25%. The
analyses identified two CNV events (CN gains on chro-
mosomes 7q11.21 and 16p11.2) with significant fre-
quency differences between LS/HNPCC cases (n = 96)
and healthy controls (n = 384), see Table 3. The CN gain
on chromosome 7q11.21 spans 140 kb and contained 7
SNP probes (see Figure 1A). It was observed in 28% of
the LS/HNPCC cases, while none of the controls
displayed a gain in this region (Nexus; p = 4.93E-21 and
QuantiSNP; p = 5.00E-06). The CN gain on chromosome
16p11.2 spanned 82 kb and contained 122 probes: 6
SNP probes and 116 cnv probes (see Figure 1B). It was
observed in 46% of the LS/HNPCC cases, whereas the
reverse copy number state was observed in the control
group; CN loss in 23% of the controls (Nexus; p = 3.60E-
20 and QuantiSNP; p < 1.00E-16). The two significant
CNVs were both CN gains and located in regions
containing no annotated genes, miRNA’s or CpG islands.
For both CNVs, a higher frequency was observed in the
LS/HNPCC cases compared to controls.
Overall Copy Number Variation burden
Data outputs from Nexus and QuantiSNP were used
when calculating the overall CNV burden (total CNV
length, average CNV length and number of observed
CNV events) in each group of samples. Comparison
of total and average CNV length revealed a greater
total genomic CNV length (Nexus; p = 0.0006 and
QuantiSNP; p = 0.0001) and a greater average CNV
length (Nexus; p = 0.0044 and QuantiSNP; p ≤ 0.0001)
in the cases compared to the controls, see Table 4. A
higher number of CNV events was also observed in
LS/HNPCC cases compared to controls utilising the
Nexus program (p ≤ 0.0001) but not with QuantiSNP
(p = 0.8981), see Table 4. The frequency of called
events differed substantially between the methods,
with Nexus calling a mean 233 CNVs in cases and a
mean 50 CNVs in controls, while the equivalent fre-
quencies for QuantiSNP were a mean 16 CNVs each
called in cases and controls.
We also compared the total and average CNV length
between mutation positive LS (MMR+) cases (n = 60)Table 3 Summary of the CN events were the frequency of the









7q11.21 61,682,801-61,827,108 140 kb CN Gain
16p11.2 32,411,929-32,504,942 82.0 kb CN Gain
Nexus protocol 5 [53] was used to compare the sample groups. No genes, microRNand mutation negative HNPCC (MMR-) cases (n = 36).
No difference was observed in the total length of CNV’s
(Nexus; p = 0.8630 and QuantiSNP; p = 0.6355), but a
significantly greater average length was observed in
the MMR positive group for QuantiSNP (p = 0.0069)
but not for Nexus (p = 0.6302). When comparing the
total number of CNV events between the two groups
Nexus suggested a trend towards significantly more
events for the MMR negative group (p = 0.0509), but
the converse was observed in QuantiSNP (p = 0.0021)
and to a much lesser degree; likely reflected by the
marked difference in event frequencies called by the
two methods. See Table 4.
Unique Copy Number Variation burden
We also conducted analyses of CNV burden that in-
cluded only unique/rare CNV events (defined as CNV
events showing 0% overlap with previously reported
CNV’s). These analyses were restricted to Nexus output,
due to the difficulty of defining unique CNVs using
QuantiSNP. The total length, average length and num-
ber of CNVs were much higher in LS/HNPCC samples
compared to controls, see Table 5. The mean total length
in LS/HNPCC patients was 2.9 Mb greater than in the
controls (p ≤ 0.0001), the average CNV length was 9 kb
greater than in controls (p ≤ 0.0001), and there were
70 more CNVs in LS/HNPCC patients (mean 84) com-
pared to controls (mean 14), p ≤ 0.0001. No significant
difference was observed in the total and average length
between MMR + LS cases vs. MMR- HNPCC cases
but the number of CNV events was higher in MMR-
cases (mean 117) compared to MMR + cases (mean 64),
p = 0.0007.
Validation of CN gains on chromosome 7q11.21 and
16p11.2
The concentrations of all the DNA samples were
normalised and twice confirmed using Epoch™ Spectro-
photometer System (Take3™ Multi-Volume Plate). DNA
quality was considered to be good (sample purity:
OD260/280 = 1.8-2.0). Neither of the TaqMan
W Custom
CN Assays validated the array results. The assay
designed for the CN gain on chromosome 7q11.21 pro-
duced average confidence values across the samples of





96 HNPCC/LS cases vs. 384 Controls
Nexus QuantiSNP
28% 0% p=4.93E-21 p=5.00E-06
46% CN Loss 23% p=3.6E-20 p<1.00E-16
A or CPG islands are present in any of the CN regions listed in the table.
Figure 1 Displays log-R-ratio (LRR)/B-allele frequency (BAF) traces of the two significant regions, in addition to call start, call end, call
length, probe count and probe median for; A) CN gain on chromosome 7q11.21 and B) CN Gain on chromosome 16p11.2.
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Only two of the expected twenty-two (9%) cases
displayed a CN of 3 (3CN), one with a confidence
level of <50% and the other >99%. Two samples indi-
cated a 3CN (confidence level of 95 and 99%) when
initial array results suggested a normal CN state. Re-
peating the assay produced CN calls that were incon-
sistent with those of the initial run. Attempting to
validate the CN gain on chromosome 16p11.2 pro-
duced low confidence values across the samples (aver-
age confidence values is 80%, standard deviation =
24%), and only 12 of the expected 36 (33%) samples
demonstrated a CN > 2 (confidence values ranging
from <50 – 89%). Three samples indicated a CN of 3
(all with a confidence level of <50%) when initial array
results suggested a normal CN state.
Dataset re-analysed on Nexus v.6.1
Nexus v.6.1, a specific version with linear correction,
became available in the latter stages of this project.
The dataset was re-analysed with the same analysis
settings as before. Nexus v.6.1 allows linear correction
to be applied; the bias values in the columns of the
correction file (e.g. GC%, PCR fragment GC%, frag-
ment length) are used to create a linear model whose
parameters are estimated using the least squares
method. The estimate is then subtracted from the
probe Log2Ratio to obtain the corrected probe values.
Linear correction was applied to our dataset, resulting
in 9% of the probes being discarded. Interestingly, the
CN gain on chromosome 16p11.2 was not observed in
this analysis and after further investigation we saw that
all of the cnv probes in this region were discarded.
Only the SNP probes were retained and they did not
display a CN gain. The CN gain on chromosome
7q11.21 identified by Nexus v.5.0 was still evident, but
in fewer samples than before and the region no longer
display a significant frequency difference between cases
and controls.
Comparison of the most significant results
Due to the inconsistency in the results between Nexus
and QuantiSNP software’s we decided to compare the
most significant results in more detail by repeating the as-
sociation analysis between cases and controls with a differ-
ential threshold of 10%, see Table 6. We procured a table
of CNVs showing significant frequency differences at
p < 1x10E-10 from the Nexus output (17 CNVs) and com-
pared it to QuantiSNP results. In 8 out of 13 CNV regions
QuantiSNP called longer regions than Nexus and in 4
CNV regions from Nexus output no overlapping CNVs
was detected in the QuantiSNP results. Frequency differ-
ences in cases and controls can be observed between the
software’s, see Table 6.Discussion
The potential discovery of CNVs associated with HNPCC/
LS would represent a significant advance in the search for
genetic loci associated with disease expression. In the
current study, using Illumina SNP arrays we identified
two CN gains (7q11.21 and 16p11.2) with significant fre-
quency differences between cases and controls. The CN
gain on chromosome 16p11.2 could not be validated with
a CN assay and was not evident when the dataset was re-
analysed on a newer version of Nexus software (v6.1) and
is therefore considered to be a false positive observation
from our primary analyses. False CNV calling may be
caused by intensity fluctuations on SNP arrays, which
have been shown to occur as a result of the GC content of
probed sequences, the position of the SNP in the probe
and algorithms used to analyse array signals [55]. It is
likely that the detected CN gain at chromosome 16p is an
artefact of some or all of these phenomena, and this is
supported by the exclusion of these probes when Nexus
6.1 linear correction was applied.
The CN gain on chromosome 7q11.21 could not be
validated by TaqMan assay but is still evident when re-
analysed on Nexus v6.1 (18% of cases still have CN gain,
while none of the controls display a CN gain in the same
region). Unlike TaqManW Pre-Designed and Custom
Plus assays, the Custom assay design used for these vali-
dations does not go through genome quality checks as
the others and is designed on a masked sequence pro-
vided by the customer. The Custom assay for the CN
gain on chromosome 7q11.21 demonstrated a weakness
in its reproducibility (low confidence scores and incon-
sistent calls when repeated), which may or may not be a
result of DNA sequence-specific complications. These
results are evidence of loci specific, elevated rates of
false detection for both platforms used, and since all
sample concentrations were equilibrated and pipetting
between plates was consistent, a technical cause of this
inconsistency could not be identified. Due to the diffi-
culty designing a CN assay in the two regions, only one
CN assay was designed in each region. This is a possible
limitation in the attempt to validate the results, as two
assays within the segment and one assay outside the seg-
ment (as negative control) would have been optimal.
Another method that was available to validate the CN
gains at 7q11.21 and 16p11.2 was Affymetrix 2.7 M array
results from another project (unpublished data) that in-
cluded 30 of our cases. Neither of the two regions is cov-
ered by this array – and when further investigated,
Affymetrix informed that the probe performance over
these regions was not optimal. The Applied Biosystems
Custom Plus assay design service was unable to design
suitable assays for these regions, perhaps indicating a
similarly reduced capacity for optimal data acquisition
and may be reflective of the poor data obtained.
Table 4 CNV burden
Sample group Total CNV length Average CNV length of CNVs Number of CNV’s
Software Nexus QuantiSNP Nexus QuantiSNP Nexus QuantiSNP
HNPCC vs. Controls p = 0.0006 p = 0.0001 p = 0.0044 p ≤ 0.0001 p ≤ 0.0001 p = 0.8981
96 LS/HNPCC probands
Mean (95% CI) 31.2 Mb (15.4 – 46.9 Mb) 1.4 Mb (1.2-1.7 Mb) 82.5 kb (68.5-96.5 kb) 87.8 kb (75.0-100.6 kb) 233 (186–281) 16 (14–17)
384 Healthy controls
3.1 Mb (2.7-3.6 Mb ) 900 kb (847–953 Kb) 61.7 kb (59,6-63,7 kb) 56.9 kb (53.7-60.2 kb) 50 (46–54) 16 (15–16)
Mean (95% CI)
60 MMR + vs. 36 MMR- p = 0.8630 p = 0.6355 p = 0.6302 p = 0.0069 p = 0.0509 p = 0.0021
60 MMR + LS probands
Mean (95% CI) 30.0 Mb (11.7-48.3 Mb) 1.4 Mb (1.0-1.7 Mb) 85.3 kb (68.7-101.8 kb) 72.4 kb (61.0-83.4 kb) 199 (135–264) 17 (15–19)
36 MMR- HNPCC probands
Mean (95% CI) 33.0 Mb (2.9-63.1 Mb) 1.5 Mb (1.1-1.9 Mb) 77.9 kb (51.6-104.1 kb) 11.3 kb (86.2-140.6 kb) 290 (224–356) 13 (11–14)
Nexus and QuantiSNP output analysis of overall CNV burden; total length of CNV’s, average length of CNV’s and number of CNV’s in Lynch syndrome/HNPCC patients (n = 96) vs. Controls (n = 384) and between MMR +





















Table 5 Unique CNV burden
Sample group Total CNV length Average length of CNVs Number of CNV’s
96 LS/HNPCC vs. 384 Controls p ≤ 0.0001 p ≤ 0.0001 p ≤ 0.0001
96 LS/HNPCC proband
Mean (95% CI) 3.3 Mb (2.5-4.1 Mb) 33.3 kb (31.2-35.4 kb) 84 (68–100)
384 Controls
Mean (95% CI) 392.3 kb (323.2-461.3 kb) 23.4 kb (22.3-24.4 kb) 14 (12–16)
60 MMR + vs. 36 MMR- LS/HNPCC p = 0.0597 p = 0.9115 p = 0.0007
60 MMR + LS/HNPCC probands
Mean (95% CI) 2.8 Mb (1.7-3.8 Mb) 33.2 kb (30.2-36.2 kb) 64 (44–83)
36 MMR- LS/HNPCC probands
Mean (95% CI) 4.3 Mb (3.1-5.5 Mb) 33.4 kb (30.9-36.0 kb) 117 (93–140)
Nexus output analysis of unique CNV burden; total length of CNV’s, average length of CNV’s and number of CNV’s in HNPCC patients (n = 96) vs. Controls (n = 384)
and between MMR + individuals (n = 60) vs. MMR- individuals (n = 36).
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chromosomal region where there are no annotated
genes/miRNA/CpG islands, but the CN gain is down-
stream of a CpG island (CpG: 139) and upstream of the
gene LOC643955 (function unknown). The importance
of these intergenic regions is poorly understood but they
may be involved in regulating the expression of up- or
down-stream genomic regions [56] or be in linkage dis-
equilibrium with disease associated regions. CNVs in the
region have previously been reported in control popula-
tions [57]. Chromosome 7q11-21 has previously been as-
sociated with cancer [58,59] and interestingly, both
regions identified in the current study (7q11.21 and
16p11.2) have been found as CN gains in small bowel
adenocarcinomas [60], which raises questions whether
this is evidence in favour of the findings of the current
study, or calls into question the stringency of the ana-
lysis which reported it.
It has been suggested that the overall CNV burden
creates a differing sensitised background during develop-
ment, leading to different thresholds of disease [61]. In
the current study we observed that HNPCC/LS cases
have a greater overall CNV burden and unique/rare
CNV burden compared to controls. This is consistent
with previous reports for other complex genetic disor-
ders. For example, individuals with schizophrenia have a
greater genomic burden of structural variation compared
to controls [62] and rare CNVs have been observed in
schizophrenia patients but not controls, supporting a
disease model incorporating the effects of multiple, rare,
highly penetrant variants [63]. Few studies have investi-
gated germline CNVs and cancer risk, but the total
number of germline CNVs have been found to be higher
in patients with Li-Fraumeni syndrome compared to
controls [64]. A large CNV burden has also been posi-
tively correlated with the severity of childhood disabil-
ities [24]. In the current study, the high overall CNVburden in HNPCC/LS patients could be due to their
MMR deficiency arising from mutations in MMR genes,
supporting the idea that deficiency of MMR occurs first
and the adenoma evolves from the MMR-deficient cell
[65]. Therefore we tested the overall difference in the
CNV burden between MMR + LS patients and MMR-
HNPCC patients. The total and average CNV length was
not different between the two groups but the number of
CNV events was. Interestingly, Nexus Software analysis
suggested that MMR- HNPCC cases had a greater
unique/rare CNV burden than MMR + probands, which
could be an indication of a deficient DNA repair in these
patients despite the negative mutation screen in MMR
genes known to be associated with the disease. Because
our clinical cohort represents a highly ascertained popu-
lation that underwent CNV analyses as a result of a clin-
ical/molecular diagnosis of HNPCC/LS, the subjects are
possibly enriched for rare CNVs. However, we only cau-
tiously suggest this interpretation, due to the described
challenges with validating Nexus results.
We took a rigorous and conservative analytical ap-
proach to maximise CNV call reliability by calculating
NSR, setting the number of probes to a minimum of 5
and using two different algorithms to identify significant
CNV differences between cases and controls. Utilising
more than one algorithm in CNV calling have been ap-
plied in several studies to improve the rates of reprodu-
cibility and positive prediction [19,66-69], however it
invariably demonstrates an increase in the overall false
positive rate. Accordingly, we sought to control our
positive prediction rate by considering only those re-
gions that satisfied dual algorithm detection at respective
significance thresholds as qualifiers of association with
LS/HNPCC. Nevertheless, our findings should be
interpreted with caution as we can see considerable dif-
ferences between the CNV frequencies detected in
cases/controls in the association analysis, the total
Table 6 A table of the most significant results from the repeated association test between cases and controls including details of CNV region, cytoband
location, event, region length, frequency in cases and controls, p-value and % of CNV overlap from Nexus output and CNV region, number of SNPs in










p-value % of CNV
Overlap*







chr1:1,082,510-1,109,835 p36.33 CN Loss 27325 14.6 0.0 7.33E-11 100 chr1:1,064,487-1,096,336 8 0.0 0.3 0.62
chr1:192,838,687-193,008,078 q31.3 CN Gain 169391 15.6 0.0 1.29E-11 8 No overlapping CNV ─ 0.0 0.0 NA
chr3:90,524,766-90,576,572 p11.1 CN Gain 51806 14.6 0.0 7.33E-11 100 chr3:90,421,209-90,576,572 19 16.7 0.0 4.06E-16
chr5:104,661,153-104,676,508 q21.3 CN Gain 15355 14.6 0.0 7.33E-11 100 chr5:104,667,691-104,675,112 5 1.0 0.0 0.05
chr6:31,945,137-31,947,946 p21.32 CN Loss 2809 14.6 0.0 7.33E-11 0 No overlapping CNV ─ 0.0 0.0 NA
chr6:62,208,962-62,262,670 q11.1 CN Gain 53708 17.7 0.5 4.66E-11 100 chr6:62,176,064-62,260,258 11 15.6 0.0 3.55E-15
chr7:61,644,365-62,087,478 q11.21 CN Gain 443113 28.1 0.0 4.93E-21 100 chr7:61,667,556-61,990,710 18 7.3 0.0 9.79E-08
chr8:145,462,650-145,641,721 q24.3 CN Loss 179071 17.7 0.0 3.87E-13 100 No overlapping CNV ─ 0.0 0.0 NA
chr9:138,620,572-138,764,838 q34.3 CN Loss 144266 15.6 0.0 1.29E-11 100 No overlapping CNV ─ 0.0 0.0 NA
chr9:9,793,206-9,814,023 p23 CN Gain 20817 15.6 0.0 1.29E-11 100 chr9:9,778,666-9,809,028 21 1.0 0.0 0.05
chr11:50,339,475-50,370,127 p11.12 CN Gain 30652 21.9 0.0 3.08E-16 100 chr11:50,654,023-50,961,054 6 5.2 0.0 6.94E-06
chr11:54,468,566-54,554,469 q11 CN Gain 85903 20.8 0.3 3.30E-14 100 chr11:54,468,566-54,533,370 19 13.5 0.3 4.62E-12
chr12:36,616,479-36,650,608 q12 CN Gain 34129 19.8 0.5 1.66E-12 100 chr12:36,301,572-36,667,312 23 9.4 0.3 2.24E-08
chr14:104,706,668-104,721,437 q32.33 CN Loss 14769 14.6 0.0 7.33E-11 100 chr14:104,688,087-104,717,224 10 1.0 0.0 0.05
chr16:32,405,679-32,504,942 p11.2 CN Gain 99263 45.8 4.2 1.98E-22 100 chr16:32,443,063-32,460,991 23 45.8 20.1 1.96E-07
chr18:15,069,391-15,093,669 p11.21 CN Loss 24278 14.6 0.0 7.33E-11 100 chr18:15,045,092-15,219,051 20 8.3 0.0 1.17E-08
chr19:32,445,280-32,903,861 q12 CN Gain 458581 24.0 0.3 1.65E-16 100 chr19:32,520,504-32,810,457 28 11.5 0.3 3.27E-10
* Defined by Nexus as being reported in public repositories as being normal polymorphic in the "normal population".
Footnote:
The table shows CNVs showing significant frequency differences (at P < 1x10E-10) between HNPCC cases and controls in the analysis using Nexus.





















Talseth-Palmer et al. BMC Medical Genomics 2013, 6:10 Page 11 of 13
http://www.biomedcentral.com/1755-8794/6/10length, average length and the number of CNVs called
between the two software programs used for analysis.
Reassuringly, the discrepancies we observed are consist-
ent with the results of other recent studies that have
attempted to use convergence across multiple algorithms
to identify valid CNV calls [67-69]. The source of these
discrepancies is due to the differing sensitivities of algo-
rithms to the inherent variations in relative fluorescence
between co-assayed genomic loci on SNP arrays.
To compare the algorithms used in the current study,
Nexus uses a proprietary CBS based algorithm to divide
chromosomal data into segments whose median LRR
values are significantly different from adjacent segments.
CNVs are defined using numerous one-size-fits-all user
defined thresholds (see methods) and may therefore be
susceptible to CNV call reliability fluctuations according
to data quality. The Nexus algorithm only considers sin-
gle samples for CNV calling and does not draw on col-
lective data for greater call confidence. Conversely,
QuantiSNP uses a HMM where aberrations are defined
as excursions from the null state that satisfy multiple pa-
rameters learnt from the input data and confidence is
heightened if the aberrations are detected in multiple
samples. Additionally, there are only two user defined
thresholds (the characteristic length parameter (2 MB
default) and Log-Bayes Factor), which serve to reduce
the false positive error rate at differing stages of the ana-
lysis [52].
The challenge seems to be a combination of the inher-
ent inaccuracy of measuring signal intensity using geno-
typing data from SNP arrays and systematic differences
between statistical algorithms. Accordingly, the observed
higher Type I error rate by Nexus in the current study
may be due to the lack of control for false positives, the
rigidity of its user-defined thresholds which do not adapt
in line with data quality and a lack of confidence testing
of aberrations (that is, the only significance testing is ap-
plied at the segmentation stage, not when the LRR ± cut-
offs indicate CN gain or loss). In recent comparisons
[34,70], both programs utilised in the current study have
performed well compared to other algorithms and we
used settings consistent with those previously reported.
The recent study by Kim et al. [69] suggests that conver-
gent CNV calls across at least three algorithms should
be obtained before undertaking association analysis as
only ~10% of CNVs called using two algorithms were
verified by a third. Such low convergence likely reflects a
combination of type I and type II error across the dis-
covery and validation analysis. Kim et al. [69] do how-
ever show that validity can be increased by increasing
the CNV filtering criterion to require the inclusion of at
least 7 probes, suggesting that better validity may have
resulted from applying a third algorithm and requiring
called CNVs to contain at least 7 consecutive probes.New software for analysing CNVs is being rapidly de-
veloped [34,70] and as no gold standard has yet been
established, CNV analyses remains challenging and the
results difficult to interpret. Other possible limitations of
our study are the control population, the modest sample
size and the potential for false negative results due to
strict analytical parameters. The controls were healthy
individuals at the time of sampling but may develop can-
cer in the future, which would be expected to reduce
power of our analyses. However, all controls were aged
>55 years, which reduces the potential impact of mis-
classification bias.
The genomic region on chromosome 7q11.21 requires
further investigation to prove the association with the
investigated disease and should not be dismissed due to
its location in an intergenic region. The HNPCC/LS
cases have a greater burden of CNV across their ge-
nomes compared to controls which is supporting the no-
tion of higher genomic instability in these patients due
to an inadequate DNA repair process. The technology is
improving rapidly, but until next-generation sequencing
is available and widely used in clinical diagnostic testing,
inspecting the overall CNV burden in individuals with a
clinical diagnosis of HNPCC/LS could become a rapid
and cost-efficient screening method for identifying fam-
ilies for genetic testing. Future research should explore
the identified candidate locus on chromosome 7q11.21
further as well as consider whether high CN at this locus
increases the risk of disease development in the context
of HNPCC/LS families.
Conclusion
In conclusion, we have identified a greater CNV burden in
HNPCC/LS cases compared to controls supporting the
notion of higher genomic instability in these patients due
to an inadequate DNA repair process. One intergenic
locus on chromosome 7q11.21 is possibly associated with
disease risk in patients diagnosed with HNPCC/LS and
should therefore not be dismissed as a false positive with-
out further investigation. The results from this study high-
light the complexities of fluorescent based CNV analyses;
the inefficiency of both CNV detection methods to repro-
ducibly detect observed CNVs demonstrates the need for
sequence data to be considered alongside intensity data to
avoid false positive results.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
BTP conceived the study, participated in its design and carried out the
molecular genetic studies, analysis and drafted the manuscript. EGH and TJE
participated in the design and analysis of the study. MM and JA: Control
collection and material support. DMG and ALM participated in the
completion of the study. CM and AS: Patient collection and material support.
RJS participated in study design and coordination. All authors read and
approved the final manuscript.
Talseth-Palmer et al. BMC Medical Genomics 2013, 6:10 Page 12 of 13
http://www.biomedcentral.com/1755-8794/6/10Acknowledgment
The authors would like to thank the participants for contributing to this study.Funding
This study was supported by grants from the Hunter Medical Research
Institute, Glady’s M. Brawn Memorial Fund through the University of
Newcastle and the National Health and Medical Research Council.
Author details
1School of Biomedical Sciences and Pharmacy, University of Newcastle,
Newcastle, NSW, Australia. 2Hunter Medical Research Institute, John Hunter
Hospital, Newcastle, NSW, Australia. 3School of Medicine and Public Health,
University of Newcastle, Newcastle, NSW, Australia. 4Food and Nutritional
Sciences, Preventative Health Flagship & CSIRO, North Ryde, NSW, Australia.
5Hunter Area Pathology Service, Hunter New England Area Health, New
Lambton Heights, NSW, Australia. 6University of NSW, St Vincent’s Hospital
Clinical School, Sydney, Australia. 7Hunter New England Family Cancer
Service, Newcastle, NSW, Australia.
Received: 27 August 2012 Accepted: 18 March 2013
Published: 26 March 2013References
1. Dhami P, Coffey AJ, Abbs S, Vermeesch JR, Dumanski JP, Woodward KJ,
Andrews RM, Langford C, Vetrie D: Exon array CGH: detection of copy-
number changes at the resolution of individual exons in the human
genome. Am J Hum Genet 2005, 76(5):750–762.
2. Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, Scherer SW,
Lee C: Detection of large-scale variation in the human genome. Nat
Genet 2004, 36(9):949–951.
3. Stankiewicz P, Lupski JR: Molecular-evolutionary mechanisms for genomic
disorders. Curr Opin Genet Dev 2002, 12(3):312–319.
4. Wilson GM, Flibotte S, Chopra V, Melnyk BL, Honer WG, Holt RA: DNA copy-
number analysis in bipolar disorder and schizophrenia reveals aberrations in
genes involved in glutamate signaling. Hum Mol Genet 2006, 15(5):743–749.
5. Talseth-Palmer B, Scott R: Genetic variation and its role in malignancy. Int
J Biomed Sci 2011, 7(3):158–171.
6. Redon R, et al: Global variation in copy number in the human genome.
Nature 2006, 444(7118):444–454.
7. Feuk L, Carson AR, Scherer SW: Structural variation in the human genome.
Nat Rev Genet 2006, 7(2):85–97.
8. Lou H, Li S, Yang Y, Kang L, Zhang X, Jin W, Wu B, Jin L, Xu S: A map of copy
number variations in Chinese populations. PLoS One 2011, 6(11):e27341.
9. Stranger BE, Forrest MS, Dunning M, Ingle CE, Beazley C, Thorne N, Redon R,
Bird CP, de Grassi A, Lee C, Tyler-Smith C, Carter N, Scherer SW, Tavare S,
Deloukas P, Hurles ME, Dermitzakis ET: Relative impact of nucleotide and
copy number variation on gene expression phenotypes. Science 2007,
315(5813):848–853.
10. Yang TL, Chen XD, Guo Y, Lei SF, Wang JT, Zhou Q, Pan F, Chen Y, Zhang
ZX, Dong SS, Xu XH, Yan H, Liu X, Qiu C, Zhu XZ, Chen T, Li M, Zhang H,
Zhang L, Drees BM, Hamilton JJ, Papasian CJ, Recker RR, Song XP, Cheng J,
Deng HW: Genome-wide copy-number-variation study identified a
susceptibility gene, UGT2B17, for osteoporosis. Am J Hum Genet 2008,
83(6):663–674.
11. Zhang F, Gu W, Hurles ME, Lupski JR: Copy number variation in human
health, disease, and evolution. Annu Rev Genomics Hum Genet 2009,
10:451–481.
12. Thean LF, Loi C, Ho KS, Koh PK, Eu KW, Cheah PY: Genome-wide scan
identifies a copy number variable region at 3q26 that regulates PPM1L
in APC mutation-negative familial colorectal cancer patients. Genes
Chromosomes Cancer 2010, 49(2):99–106.
13. Perry GH, Dominy NJ, Claw KG, Lee AS, Fiegler H, Redon R, Werner J,
Villanea FA, Mountain JL, Misra R, Carter NP, Lee C, Stone AC: Diet and the
evolution of human amylase gene copy number variation. Nat Genet
2007, 39(10):1256–1260.
14. Almal SH, Padh H: Implications of gene copy-number variation in health
and diseases. J Hum Genet 2012, 57(1):6–13.
15. Bronstad I, Wolff AS, Lovas K, Knappskog PM, Husebye ES: Genome-wide
copy number variation (CNV) in patients with autoimmune Addison's
disease. BMC Med Genet 2011, 12:111.16. Hai R, Pei YF, Shen H, Zhang L, Liu XG, Lin Y, Ran S, Pan F, Tan LJ, Lei SF,
Yang TL, Zhang Y, Zhu XZ, Zhao LJ, Deng HW: Genome-wide association
study of copy number variation identified gremlin1 as a candidate gene
for lean body mass. J Hum Genet 2012, 57(1):33–37.
17. Jiang Q, Ho YY, Hao L, Nichols Berrios C, Chakravarti A: Copy number
variants in candidate genes are genetic modifiers of Hirschsprung
disease. PLoS One 2011, 6(6):e21219.
18. Craddock N, et al: Genome-wide association study of CNVs in 16,000
cases of eight common diseases and 3,000 shared controls. Nature 2010,
464(7289):713–720.
19. Buizer-Voskamp JE, Muntjewerff JW, Strengman E, Sabatti C, Stefansson H,
Vorstman JA, Ophoff RA: Genome-wide analysis shows increased
frequency of copy number variation deletions in Dutch schizophrenia
patients. Biol Psychiatry 2011, 70(7):655–662.
20. Dauber A, Yu Y, Turchin MC, Chiang CW, Meng YA, Demerath EW, Patel SR,
Rich SS, Rotter JI, Schreiner PJ, Wilson JG, Shen Y, Wu BL, Hirschhorn JN:
Genome-wide association of copy-number variation reveals an
association between short stature and the presence of low-frequency
genomic deletions. Am J Hum Genet 2011, 89(6):751–759.
21. Felekkis K, Voskarides K, Dweep H, Sticht C, Gretz N, Deltas C: Increased
number of microRNA target sites in genes encoded in CNV regions.
Evidence for an evolutionary genomic interaction. Mol Biol Evol 2011,
28(9):2421–2424.
22. Consortium TISISC: Rare chromosomal deletions and duplications
increase risk of schizophrenia. Nature 2008, 455(7210):237–241.
23. Pinto D, et al: Functional impact of global rare copy number variation in
autism spectrum disorders. Nature 2010, 466(7304):368–372.
24. Girirajan S, Brkanac Z, Coe BP, Baker C, Vives L, Vu TH, Shafer N,
Bernier R, Ferrero GB, Silengo M, Warren ST, Moreno CS, Fichera M,
Romano C, Raskind WH, Eichler EE: Relative burden of large CNVs on
a range of neurodevelopmental phenotypes. PLoS Genet 2011, 7(11):
e1002334.
25. Kawamura Y, Otowa T, Koike A, Sugaya N, Yoshida E, Yasuda S, Inoue K,
Takei K, Konishi Y, Tanii H, Shimada T, Tochigi M, Kakiuchi C, Umekage T, Liu
X, Nishida N, Tokunaga K, Kuwano R, Okazaki Y, Kaiya H, Sasaki T: A
genome-wide CNV association study on panic disorder in a Japanese
population. J Hum Genet 2011, 56(12):852–856.
26. Ghoussaini M, et al: Genome-wide association analysis identifies three
new breast cancer susceptibility loci. Nat Genet 2012, 44(3):312–318.
27. Ku CS, Loy EY, Pawitan Y, Chia KS: The pursuit of genome-wide
association studies: where are we now? J Hum Genet 2010, 55(4):195–206.
28. Houlston RS, et al: Meta-analysis of genome-wide association data
identifies four new susceptibility loci for colorectal cancer. Nat Genet
2008, 40(12):1426–1435.
29. Houlston RS, et al: Meta-analysis of three genome-wide association
studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2,
12q13.13 and 20q13.33. Nat Genet 2010, 42(11):973–977.
30. Broderick P, Carvajal-Carmona L, Pittman AM, Webb E, Howarth K, Rowan A,
Lubbe S, Spain S, Sullivan K, Fielding S, Jaeger E, Vijayakrishnan J, Kemp Z,
Gorman M, Chandler I, Papaemmanuil E, Penegar S, Wood W, Sellick G,
Qureshi M, Teixeira A, Domingo E, Barclay E, Martin L, Sieber O, Kerr D, Gray
R, Peto J, Cazier JB, Tomlinson I, Houlston RS: A genome-wide association
study shows that common alleles of SMAD7 influence colorectal cancer
risk. Nat Genet 2007, 39(11):1315–1317.
31. Tenesa A, et al: Genome-wide association scan identifies a colorectal
cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and
18q21. Nat Genet 2008, 40(5):631–637.
32. Tomlinson IP, et al: A genome-wide association study identifies colorectal
cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet
2008, 40(5):623–630.
33. Cooper GM, Mefford HC: Detection of copy number variation using SNP
genotyping. Methods Mol Biol 2011, 767:243–252.
34. Dellinger AE, Saw SM, Goh LK, Seielstad M, Young TL, Li YJ: Comparative
analyses of seven algorithms for copy number variant identification
from single nucleotide polymorphism arrays. Nucleic Acids Res 2010,
38(9):e105.
35. Berg M, Agesen TH, Thiis-Evensen E, Merok MA, Teixeira MR, Vatn MH,
Nesbakken A, Skotheim RI, Lothe RA: Distinct high resolution genome
profiles of early onset and late onset colorectal cancer integrated with
gene expression data identify candidate susceptibility loci. Mol Cancer
2010, 9:100.
Talseth-Palmer et al. BMC Medical Genomics 2013, 6:10 Page 13 of 13
http://www.biomedcentral.com/1755-8794/6/1036. Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, Kane M,
Kolodner R: The human mutator gene homolog MSH2 and its association
with hereditary nonpolyposis colon cancer. Cell 1993, 75(5):1027–1038.
37. Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK, Kane M,
Earabino C, Lipford J, Lindblom A: Mutation in the DNA mismatch repair
gene homologue hMLH1 is associated with hereditary non-polyposis
colon cancer. Nature 1994, 368(6468):258–261.
38. Peltomaki P, Vasen HF: Mutations predisposing to hereditary
nonpolyposis colorectal cancer: database and results of a collaborative
study. The International Collaborative Group on Hereditary Nonpolyposis
Colorectal Cancer. Gastroenterology 1997, 113(4):1146–1158.
39. Peltomaki P: Deficient DNA mismatch repair: a common etiologic factor
for colon cancer. Hum Mol Genet 2001, 10(7):735–740.
40. Lawes DA, SenGupta SB, Boulos PB: Pathogenesis and clinical
management of hereditary non-polyposis colorectal cancer. Br J Surg
2002, 89(11):1357–1369.
41. Ligtenberg MJ, Kuiper RP, Chan TL, Goossens M, Hebeda KM, Voorendt M,
Lee TY, Bodmer D, Hoenselaar E, Hendriks-Cornelissen SJ, Tsui WY, Kong CK,
Brunner HG, van Kessel AG, Yuen ST, van Krieken JH, Leung SY,
Hoogerbrugge N: Heritable somatic methylation and inactivation of
MSH2 in families with Lynch syndrome due to deletion of the 3' exons
of TACSTD1. Nat Genet 2009, 41(1):112–117.
42. Jiricny J: The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol
2006, 7(5):335–346.
43. Vasen HF, Watson P, Mecklin JP, Lynch HT: New clinical criteria for
hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome)
proposed by the International Collaborative group on HNPCC.
Gastroenterology 1999, 116(6):1453–1456.
44. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J,
Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J,
Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen
HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S: Revised Bethesda
Guidelines for hereditary nonpolyposis colorectal cancer (Lynch
syndrome) and microsatellite instability. J Natl Cancer Inst 2004,
96(4):261–268.
45. Ku CS, Cooper DN, Wu M, Roukos DH, Pawitan Y, Soong R, Iacopetta B:
Gene discovery in familial cancer syndromes by exome sequencing:
prospects for the elucidation of familial colorectal cancer type X. Mod
Pathol 2012, 25(8):1055–1068.
46. Dunlop MG: Guidance on gastrointestinal surveillance for hereditary non-
polyposis colorectal cancer, familial adenomatous polypolis, juvenile
polyposis, and Peutz-Jeghers syndrome. Gut 2002, 51(Suppl 5):V21–V27.
47. Dunlop MG, Farrington SM, Nicholl I, Aaltonen L, Petersen G, Porteous M,
Carothers A: Population carrier frequency of hMSH2 and hMLH1
mutations. Br J Cancer 2000, 83(12):1643–1645.
48. Alarcon F, Lasset C, Carayol J, Bonadona V, Perdry H, Desseigne F, Wang Q,
Bonaiti-Pellie C: Estimating cancer risk in HNPCC by the GRL method. Eur
J Hum Genet 2007, 15(8):831–836.
49. Obermair A, Youlden DR, Young JP, Lindor NM, Baron JA, Newcomb P, Parry
S, Hopper JL, Haile R, Jenkins MA: Risk of endometrial cancer for women
diagnosed with HNPCC-related colorectal carcinoma. Int J Cancer 2010,
127(11):2678–2684.
50. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for
extracting DNA from human nucleated cells. Nucleic Acids Res 1988,
16(3):1215.
51. McEvoy M, Smith W, D'Este C, Duke J, Peel R, Schofield P, Scott R, Byles J,
Henry D, Ewald B, Hancock S, Smith D, Attia J: Cohort profile: the hunter
community study. Int J Epidemiol 2010, 39(16):1452–1463.
52. Colella S, Yau C, Taylor JM, Mirza G, Butler H, Clouston P, Bassett AS, Seller A,
Holmes CC, Ragoussis J: QuantiSNP: an Objective Bayes Hidden-Markov
Model to detect and accurately map copy number variation using SNP
genotyping data. Nucleic Acids Res 2007, 35(6):2013–2025.
53. Darvishi K, et al: Application of Nexus copy number software for CNV
detection and analysis. In Current protocols in human genetics / editorial
board. Edited by Haines JL.; 2010:11–28. Chapter 4:Unit 4 14.
54. Andreson R, Puurand T, Remm M: SNPmasker: automatic masking of SNPs
and repeats across eukaryotic genomes. Nucleic Acids Res 2006, 34:W651–
W655. Web Server issue.
55. Jiang H, Yi M, Mu J, Zhang L, Ivens A, Klimczak LJ, Huyen Y, Stephens RM,
Su XZ: Detection of genome-wide polymorphisms in the AT-richPlasmodium falciparum genome using a high-density microarray. BMC
Genomics 2008, 9:398.
56. Auer H: Expression divergence and copy number variation in the human
genome. Cytogenet Genome Res 2008, 123(1–4):278–282.
57. Shaikh TH, Gai X, Perin JC, Glessner JT, Xie H, Murphy K, O'Hara R,
Casalunovo T, Conlin LK, D'Arcy M, Frackelton EC, Geiger EA, Haldeman-
Englert C, Imielinski M, Kim CE, Medne L, Annaiah K, Bradfield JP,
Dabaghyan E, Eckert A, Onyiah CC, Ostapenko S, Otieno FG, Santa E, Shaner
JL, Skraban R, Smith RM, Elia J, Goldmuntz E, Spinner NB, Zackai EH,
Chiavacci RM, Grundmeier R, Rappaport EF, Grant SF, White PS, Hakonarson
H: High-resolution mapping and analysis of copy number variations in
the human genome: a data resource for clinical and research
applications. Genome Res 2009, 19(9):1682–1690.
58. Friedrichsen DM, Stanford JL, Isaacs SD, Janer M, Chang BL, Deutsch K,
Gillanders E, Kolb S, Wiley KE, Badzioch MD, Zheng SL, Walsh PC, Jarvik GP,
Hood L, Trent JM, Isaacs WB, Ostrander EA, Xu J: Identification of a
prostate cancer susceptibility locus on chromosome 7q11-21 in Jewish
families. Proc Natl Acad Sci USA 2004, 101(7):1939–1944.
59. Ariza M, Llorente JL, Alvarez-Marcas C, Baragano L, Salas A, Rodriguez Prado
N, Hermsen M, Suarez C, Sampedro A: Comparative genomic hybridization
in primary sinonasal adenocarcinomas. Cancer 2004, 100(2):335–341.
60. Diosdado B, Buffart TE, Watkins R, Carvalho B, Ylstra B, Tijssen M, Bolijn AS,
Lewis F, Maude K, Verbeke C, Nagtegaal ID, Grabsch H, Mulder CJ, Quirke P,
Howdle P, Meijer GA: High-resolution array comparative genomic
hybridization in sporadic and celiac disease-related small bowel
adenocarcinomas. Clin Cancer Res 2010, 16(5):1391–1401.
61. Girirajan S, Eichler EE: Phenotypic variability and genetic susceptibility to
genomic disorders. Hum Mol Genet 2010, 19(R2):R176–R187.
62. The_International_Schizophrenia_Consortium: Rare chromosomal deletions
and duplications increase risk of schizophrenia. Nature 2008, 455(7210):
237–241.
63. Magri C, Sacchetti E, Traversa M, Valsecchi P, Gardella R, Bonvicini C, Minelli
A, Gennarelli M, Barlati S: New copy number variations in schizophrenia.
PLoS One 2010, 5(10):e13422.
64. Kuiper RP, Ligtenberg MJ, Hoogerbrugge N, Geurts Van Kessel A: Germline
copy number variation and cancer risk. Curr Opin Genet Dev, 20((3):282–289.
65. Boland CR: Lynch syndrome: new tales from the crypt. Lancet Oncol 2012,
13(6):562–564.
66. Eckel-Passow JE, Atkinson EJ, Maharjan S, Kardia SL, De Andrade M:
Software comparison for evaluating genomic copy number variation for
Affymetrix 6.0 SNP array platform. BMC Bioinforma 2011, 12:220.
67. Tsuang DW, Millard SP, Ely B, Chi P, Wang K, Raskind WH, Kim S, Brkanac Z,
Yu CE: The effect of algorithms on copy number variant detection. PLoS
One 2010, 5(12):e14456.
68. Zhang D, Qian Y, Akula N, Alliey-Rodriguez N, Tang J, Gershon ES, Liu C:
Accuracy of CNV Detection from GWAS Data. PLoS One 2011, 6(1):e14511.
69. Kim SY, Kim JH, Chung YJ: Effect of Combining Multiple CNV Defining
Algorithms on the Reliability of CNV Calls from SNP Genotyping Data.
Genomics Inform 2012, 10(3):194–199.
70. Xu Y, Peng B, Fu Y, Amos CI: Genome-wide algorithm for detecting CNV
associations with diseases. BMC Bioinforma 2011, 12:331.
doi:10.1186/1755-8794-6-10
Cite this article as: Talseth-Palmer et al.: Continuing difficulties in
interpreting CNV data: lessons from a genome-wide CNV association
study of Australian HNPCC/lynch syndrome patients. BMC Medical
Genomics 2013 6:10.
